References in periodicals archive ?
This new US patent 10,155,006 broadens the company's previous patent 9,566,280 and expands the use of Onvansertib to encompass combination therapies with any anti-androgen and androgen antagonist drug, including Zytiga, Xtandi and Erleada, for the treatment of metastatic and non-metastatic castrate-resistant prostate cancer.
This patent broadens previously issued patent by expanding the use of Onvansertib to encompass combination therapies with any anti-androgen and androgen antagonist drug for the treatment of metastatic and non-metastatic castrate-resistant prostate cancer.
Selection for androgen receptor mutations in prostate cancels treated with androgen antagonist. Cancer Res 1999;59:251 1-5.
Both androgen stimulated pro-MMP-2 expression and MMP-2 promoter activity can be abolished by the androgen antagonist bicalutamide [26].
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999;59: 2511-5.
Other forms of therapy include androgen antagonist drugs such as ketoconazole, finasteride and insulin-sensitizing drugs such as metformin.
Interestingly, when investigating substances with reported high endocrine-disrupting effects such as nonylphenol or bisphenol A (both are estrogenic) and vinclozolin (an androgen antagonist), none of the substances, with the exception of TCDD, binds to or activates the steroid receprors by > 1 % of the endogenous ligand (Table 4).
Trovagene has entered into an exclusive patent license agreement with the Massachusetts Institute of Technology, MIT, under which Trovagene has exclusive rights to develop combination therapies that include anti-androgen or androgen antagonist and a Polo-like Kinase inhibitor for the treatment of cancer.
The objectives of the first phase of the OECD validation of the Hershberger bioassay were to a) demonstrate the reproducibility and sensitivity of the responses of five male sex accessory tissues to the action of a reference androgen, TP, hereafter phase 1A; b) assess the utility, reproducibility, and sensitivity of various other measured end points within and among participating laboratories in response to the action of TP; c) study the interaction of reference TP doses with a reference androgen antagonist, FLU, on the sex accessory tissues and other end points, hereafter phase 1B; and d) select standard reference doses of TP and FLU for future studies with weakly potent agonists, antagonists, and nonandrogenic test substances.
"If hyperandrogenism drives the microbial composition of the gut, it would be interesting to determine if treatment of PCOS with androgen antagonists or oral contraceptives results in recovery of the gut microbiome and improvement of the PCOS metabolic phenotype" wrote Mr.
Torres noted that "if hyper-androgenism drives the microbial composition of the gut, it would be interesting to determine if treatment of PCOS with androgen antagonists or oral contraceptives results in recovery of the gut microbiome and improvement of the PCOS metabolic phenotype.